oxycodone and semaglutide GLP-1 Agent May Hold Opioid Use Disorder Benefit Navigating the -tides: Medication-Assisted Weight

Yes, we are witnessing a profound shift

Your care team might include a GI provider (a nurse practitioner or physician associate), a GI registered dietitian, and/or a gut-brain specialist or psychologist, all overseen by board-certified gastroenterologists

2024 JAMA Ophthalmology Study Findings The landmark Harvard Medical School study published in JAMA Ophthalmology in July 2024 provided the first rigorous scientific evidence linking semaglutide to elevated NAION risk analyzing 16,827 patients at Massachusetts Eye and Ear and revealing alarming risk multipliers that prompted global regulatory scrutiny

Wegovy European Public Assessment Report (EMA)